SELLAS Life Sciences Group, Inc. (SLS)

NASDAQ: SLS · IEX Real-Time Price · USD
1.000
-0.030 (-2.91%)
Mar 28, 2024, 1:52 PM EDT - Market open

Company Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.

The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.

The company is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group logo
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Dr. Angelos M. Stergiou M.D., ScD h.c.

Contact Details

Address:
7 Times Square, Suite 2503
New York, New York 10036
United States
Phone (646) 200-5278
Website sellaslifesciences.com

Stock Details

Ticker Symbol SLS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001390478
CUSIP Number 81642T209
ISIN Number US81642T2096
SIC Code 2834

Key Executives

Name Position
Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, President, Chief Executive Officer and Director
John Thomas Burns CPA Senior Vice President and Chief Financial Officer
Stacy E. Yeung Vice President, Associate General Counsel and Head of Compliance
Dr. Dragan Cicic M.D., MBA Senior Vice President of Clinical Development
Andrew Elnatan Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls and Quality

Latest SEC Filings

Date Type Title
Mar 28, 2024 8-K Current Report
Mar 18, 2024 424B5 Filing
Mar 15, 2024 8-K Current Report
Mar 11, 2024 8-K Current Report
Mar 8, 2024 8-K Current Report
Mar 5, 2024 8-K Current Report
Feb 16, 2024 8-K Current Report
Feb 7, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 19, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jan 8, 2024 8-K Current Report